Title:
COMBINATION THERAPIES INVOLVING L-ASPARAGINASE
Document Type and Number:
WIPO Patent Application WO/2024/015529
Kind Code:
A3
Abstract:
The present disclosure provides compositions and methods for treating cancer in a human subject comprising dosing a human subject with a monotherapy or combination therapy involving L-asparaginase. Combination therapies disclosed herein include combination therapies with functionalized or unfunctionalized L-asparaginase in combination with a BCL-XL inhibitor, a BCL-2 inhibitor, a CD20 inhibitor, an mTOR inhibitor, or another anticancer agent.
More Like This:
| JP2023545497 | Compositions and methods for treating glycogen storage disease type 1A |
| JP2022553399 | Recombinant L-asparaginase |
| JP2016014066 | USE OF UREASE FOR INHIBITING CANCER CELL GROWTH |
Inventors:
GURSAHANI HEMAMALINI (US)
VAIDYA KEDAR SHRINIWAS (US)
EBRAHIMNEJAD ALIREZA (US)
VAIDYA KEDAR SHRINIWAS (US)
EBRAHIMNEJAD ALIREZA (US)
Application Number:
PCT/US2023/027665
Publication Date:
March 07, 2024
Filing Date:
July 13, 2023
Export Citation:
Assignee:
JAZZ PHARMACEUTICALS IRELAND LTD (IE)
GURSAHANI HEMAMALINI (US)
VAIDYA KEDAR SHRINIWAS (US)
EBRAHIMNEJAD ALIREZA (US)
GURSAHANI HEMAMALINI (US)
VAIDYA KEDAR SHRINIWAS (US)
EBRAHIMNEJAD ALIREZA (US)
International Classes:
A61K38/50; A61K31/635; A61P35/00
Domestic Patent References:
| WO2019109018A1 | 2019-06-06 | |||
| WO2020132184A1 | 2020-06-25 |
Foreign References:
| CN113813268A | 2021-12-21 |
Other References:
KARPEL-MASSLER GEORG ET AL: "Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo", ONCOTARGET,, vol. 7, no. 23, 1 June 2016 (2016-06-01), pages 33512 - 33528, XP002775938, DOI: 10.18632/ONCOTARGET.9257
KANG MIN H ET AL: "Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo", NEOPLASIA, 29 March 2007 (2007-03-29), XP093092052, Retrieved from the Internet [retrieved on 20231016], DOI: 10.1182/blood-2007-
ZHANG PEIYI ET AL: "PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors", EXPLORATION OF TARGETED ANTI-TUMOR THERAPY, vol. 1, no. 4, 31 August 2020 (2020-08-31), pages 259 - 272, XP055881209, DOI: 10.37349/etat.2020.00017
KHAN SAJID ET AL: "A selective BCL-XPROTAC degrader achieves safe and potent antitumor activity", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 25, no. 12, 1 December 2019 (2019-12-01), pages 1938 - 1947, XP036953307, ISSN: 1078-8956, [retrieved on 20191202], DOI: 10.1038/S41591-019-0668-Z
FAIRLIE W. DOUGLAS ET AL: "Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 49, no. 5, 1 November 2021 (2021-11-01), GB, pages 2397 - 2410, XP093092496, ISSN: 0300-5127, Retrieved from the Internet DOI: 10.1042/BST20210750
TAO ZHI-FU ET AL: "Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity", ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 10, 8 September 2014 (2014-09-08), US, pages 1088 - 1093, XP093092506, ISSN: 1948-5875, DOI: 10.1021/ml5001867
KAROL SETH E ET AL: "Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 134, 13 November 2019 (2019-11-13), pages 2649, XP086673809, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2019-129805
EMADI ASHKAN ET AL: "Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia", BLOOD CANCER JOURNAL, NATURE PUBLISHING GROUP UK, LONDON, vol. 35, no. 7, 16 November 2020 (2020-11-16), pages 1907 - 1924, XP037500539, ISSN: 0887-6924, [retrieved on 20201116], DOI: 10.1038/S41375-020-01080-6
KANG MIN H ET AL: "Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo", NEOPLASIA, 29 March 2007 (2007-03-29), XP093092052, Retrieved from the Internet
ZHANG PEIYI ET AL: "PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors", EXPLORATION OF TARGETED ANTI-TUMOR THERAPY, vol. 1, no. 4, 31 August 2020 (2020-08-31), pages 259 - 272, XP055881209, DOI: 10.37349/etat.2020.00017
KHAN SAJID ET AL: "A selective BCL-XPROTAC degrader achieves safe and potent antitumor activity", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 25, no. 12, 1 December 2019 (2019-12-01), pages 1938 - 1947, XP036953307, ISSN: 1078-8956, [retrieved on 20191202], DOI: 10.1038/S41591-019-0668-Z
FAIRLIE W. DOUGLAS ET AL: "Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 49, no. 5, 1 November 2021 (2021-11-01), GB, pages 2397 - 2410, XP093092496, ISSN: 0300-5127, Retrieved from the Internet
TAO ZHI-FU ET AL: "Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity", ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 10, 8 September 2014 (2014-09-08), US, pages 1088 - 1093, XP093092506, ISSN: 1948-5875, DOI: 10.1021/ml5001867
KAROL SETH E ET AL: "Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 134, 13 November 2019 (2019-11-13), pages 2649, XP086673809, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2019-129805
EMADI ASHKAN ET AL: "Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia", BLOOD CANCER JOURNAL, NATURE PUBLISHING GROUP UK, LONDON, vol. 35, no. 7, 16 November 2020 (2020-11-16), pages 1907 - 1924, XP037500539, ISSN: 0887-6924, [retrieved on 20201116], DOI: 10.1038/S41375-020-01080-6
Attorney, Agent or Firm:
HAILE, Lisa A. et al. (US)
Download PDF:
Previous Patent: EFFICIENT PROCEDURE FOR THE SYNTHESIS OF HYDRAZONE-LINKED TETRAHEDRAL NANOCAGES
Next Patent: MONITORING THICKNESS IN FACE-UP POLISHING
Next Patent: MONITORING THICKNESS IN FACE-UP POLISHING